|
(1 of 2) Florida Minority Cancer Research & Training Center: Feasibility Studies
|
5P20CA192990-04
|
$165,747
|
REAMS, ROMONIA
|
FLORIDA AGRICULTURAL AND MECHANICAL UNIV
|
|
(2/2) CDU/UCLA Cancer Center Partnership to Eliminate Cancer Health Disparities
|
5U54CA143930-08
|
$704,474
|
FARIAS-EISNER, ROBIN
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
|
(6) Molecular mechanisms explaining premalignant changes in the etiology of melanoma
|
1R21CA208736-01A1
|
$146,000
|
MURPH, MANDI
|
UNIVERSITY OF GEORGIA
|
|
(PQ#3) Novel tumor intrinsic PD-L1 signals direct tumor immune cell infiltration
|
1R01CA205965-01A1
|
$650,815
|
CURIEL, TYLER
|
UNIVERSITY OF TEXAS HLTH SCIENCE CENTER
|
|
(PQ1) Cellular senescence as an initiating event in malignant transformation
|
1R21CA206013-01A1
|
$203,400
|
DAVID, GREGORY
|
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
|
|
(PQ11) Reversing exosome-mediated immune suppression - a novel strategy for cancer therapy
|
5R21CA205644-02
|
$202,439
|
WHITESIDE, THERESA
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
|
(PQ11) Targeting STING in the context of chemoradiation therapy to overcome poor preexisting immunity in mouse models of pancreatic cancer.
|
5R01CA208644-02
|
$377,438
|
CRITTENDEN, MARKA
|
PROVIDENCE PORTLAND MEDICAL CENTER
|
|
(PQ3) The role of damaged DNA in inter-individual variation of tumor immunity
|
5R01CA208756-02
|
$518,165
|
HACOHEN, NIR
|
BROAD INSTITUTE, INC.
|
|
(PQ4) Mutations in the histone chaperone DAXX drive pancreatic neuroendocrine tumors not ductal adenocarcinomas
|
5R21CA208463-02
|
$174,000
|
LOZANO, GUILLERMINA
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
(PQ5) Mitochondria in Leukemic Stem Cell Disease Progression
|
5R01CA205975-02
|
$386,619
|
GHAFFARI, SAGHI
|
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
|
|
(PQ8) Genetically faithful murine models for studying disease progression in chronic lymphocytic leukemia
|
1R01CA216273-01
|
$701,924
|
WU, CATHERINE
|
DANA-FARBER CANCER INST
|
|
(PQA-4) Organoid Omics To Detect And Defeat Ductal Pancreatic Cancer
|
5R01CA190092-04
|
$552,684
|
TUVESON, DAVID
|
COLD SPRING HARBOR LABORATORY
|
|
(PQB-3) Driver gene-induced inflammation in pancreatic cancer development
|
5R01CA184926-04
|
$765,544
|
JAFFEE, ELIZABETH
|
JOHNS HOPKINS UNIVERSITY
|
|
(PQB-4) Opposing Effects of the SASP in Cancer Progression
|
5R01CA184572-04
|
$329,925
|
HERBIG, UTZ
|
RBHS-NEW JERSEY MEDICAL SCHOOL
|
|
(PQB3) CD4 T cell response to BCR-ABL-positive Leukemia
|
5R01CA185062-04
|
$312,304
|
FARRAR, MICHAEL
|
UNIVERSITY OF MINNESOTA
|
|
(PQB5) Reconstruction of Evolutionary Networks using Cross-Sectional Genomic Data
|
5R01CA185486-04
|
$517,690
|
RABADAN, RAUL
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
(PQC-5) Zwitterionic NIR/Zr-89 Agents for Prostate Cancer Staging and Treatment
|
5R01CA185457-04
|
$640,378
|
FRANGIONI, JOHN
|
CURADEL, LLC
|
|
(PQC2) Localization as a determinant of cancer dormancy
|
5R01CA194596-03
|
$553,740
|
LIN, CHARLES
|
MASSACHUSETTS GENERAL HOSPITAL
|
|
(PQC4) Habitats in Prostate Cancer
|
5R01CA190105-04
|
$681,586
|
GILLIES, ROBERT
|
H. LEE MOFFITT CANCER CTR & RES INST
|
|
(PQD-1) Selective pressure of antiandrogens on castration resistant prostate canc
|
5R01CA185509-04
|
$258,128
|
GHOSH, PARAMITA
|
UNIVERSITY OF CALIFORNIA AT DAVIS
|
|
(PQD1) Clonal heterogeneity and targeted therapy resistance in melanoma
|
5R01CA185072-04
|
$348,312
|
SEKULIC, ALEKSANDAR
|
MAYO CLINIC ARIZONA
|
|
(PQD1) Evolution of vemurafenib resistance in circulating melanoma cells
|
5R01CA185151-04
|
$613,546
|
NOVINA, CARL
|
DANA-FARBER CANCER INST
|
|
(PQD1) lmpact of cytotoxic and targeted therapy on clonal evolution of CLL
|
5R01CA184922-04
|
$553,684
|
WU, CATHERINE
|
DANA-FARBER CANCER INST
|
|
(PQD3)Molecular Profiles associated with Long-Term Survival in pancreas Cancer
|
5R01CA185357-04
|
$398,393
|
AHUJA, NITA
|
JOHNS HOPKINS UNIVERSITY
|
|
(PQD5) Mass Profiling Melanoma Responses to Improve Therapy Choices and Prognosis
|
5R01CA185189-04
|
$483,693
|
TEITELL, MICHAEL
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
|
(PQD5) Predicting Anti-Cancer Efficacy through Tumor Profiling
|
5R01CA185353-04
|
$405,890
|
KIM, WILLIAM
|
UNIV OF NORTH CAROLINA CHAPEL HILL
|
|
0021.0001 CG 425 METAVIVOR
|
261200800001E
|
$319,219,481
|
UNKNOWN, UNKNOWN
|
LEIDOS BIOMEDICAL RESEARCH, INC.
|
|
0021.0001 CG 425 METAVIVOR
|
261200800001E
|
$319,219,481
|
UNKNOWN, UNKNOWN
|
LEIDOS BIOMEDICAL RESEARCH, INC.
|
|
0021.0001 CG 425 METAVIVOR
|
261200800001E
|
$319,219,481
|
UNKNOWN, UNKNOWN
|
LEIDOS BIOMEDICAL RESEARCH, INC.
|
|
0021.0001 CG 425 METAVIVOR
|
261200800001E
|
$319,219,481
|
UNKNOWN, UNKNOWN
|
LEIDOS BIOMEDICAL RESEARCH, INC.
|
|
1/2 NCCU-DUKE Cancer Disparities Translational Research Partnership
|
5P20CA202924-02
|
$229,982
|
WILLIAMS, KEVIN
|
NORTH CAROLINA CENTRAL UNIVERSITY
|
|
1/2 SDSU/UCSD Cancer Center Comprehensive Partnership
|
5U54CA132379-08
|
$1,258,708
|
MARTINEZ, MARIA
|
UNIVERSITY OF CALIFORNIA SAN DIEGO
|
|
1/2 The Alabama State University/UAB Comprehensive Cancer Center Partnership
|
5P20CA192973-04
|
$191,836
|
MANNE, UPENDER
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
|
1/2 U-HAND (University of Houston/MD Anderson) Program to Reduce Cancer Disparities
|
1P20CA221697-01
|
$324,559
|
REITZEL, LORRAINE
|
UNIVERSITY OF HOUSTON
|
|
1/2: Partnership to study racial/ethnic differences in GI cancer biology
|
3P20CA192994-03S1
|
$63,140
|
LI, ELLEN
|
STATE UNIVERSITY NEW YORK STONY BROOK
|
|
1/2: Partnership to study racial/ethnic differences in GI cancer biology
|
5P20CA192994-03
|
$288,919
|
LI, ELLEN
|
STATE UNIVERSITY NEW YORK STONY BROOK
|
|
2/2 Florida Minority Cancer Research & Training Center: Feasibility Studies
|
5P20CA192992-04
|
$158,966
|
ODEDINA, FOLAKEMI
|
UNIVERSITY OF FLORIDA
|
|
2/2 NCCU-DUKE Cancer Disparities Translational Research Partnership
|
5P20CA202925-02
|
$255,626
|
PATIERNO, STEVEN
|
DUKE UNIVERSITY
|
|
2/2 NCCU-LCCC Partnership in Cancer Research
|
5U54CA156733-08
|
$919,471
|
EARP, HENRY
|
UNIV OF NORTH CAROLINA CHAPEL HILL
|
|
2/2 Partnership to Study Racial/Ethnic Differences in GI Cancer Biology
|
5P20CA192996-03
|
$154,908
|
MCCOMBIE, WILLIAM
|
COLD SPRING HARBOR LABORATORY
|
|
2/2 Ponce School of Medicine-Moffitt Cancer Center Partnership
|
2U54CA163068-06
|
$1,656,304
|
MUNOZ-ANTONIA, TERESITA
|
H. LEE MOFFITT CANCER CTR & RES INST
|
|
2/2 SDSU/UCSD Cancer Center Comprehensive Partnership
|
5U54CA132384-08
|
$1,192,222
|
ARREDONDO, ELVA
|
SAN DIEGO STATE UNIVERSITY
|
|
2/2 The Alabama State University/UAB Comprehensive Cancer Center Partnership
|
5P20CA192976-04
|
$144,556
|
MISHRA, MANOJ
|
ALABAMA STATE UNIVERSITY
|
|
2/2 U-HAND (University of Houston/MD Anderson) Program to Reduce Cancer Disparities
|
1P20CA221696-01
|
$221,442
|
MCNEILL, LORNA
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
2/3 Morehouse Sch of Medicine/Tuskegee Univ/University of Alabama Ca Ctr Partnership
|
5U54CA118623-12
|
$407,680
|
TROY, ROBERTA
|
TUSKEGEE UNIVERSITY
|
|
3/3 Morehouse Sch of Medicine/Tuskegee Univ/University of Alabama Ca Ctr Partnership
|
5U54CA118948-12
|
$1,170,535
|
MANNE, UPENDER
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
|
3D Models of Immunotherapy
|
1U01CA214369-01
|
$574,412
|
MOONEY, DAVID
|
HARVARD UNIVERSITY
|
|
3D Prostate Histochemometry to Predict Disease Recurrence
|
5R01CA197516-02
|
$400,626
|
BHARGAVA, ROHIT
|
UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN
|
|
402 -- A PHASE I TRIAL OF THE SAFETY IMMUNOGENICITY OF RG1-VLP... (PROTOCOL UWI2016-08-02). CONTRACTOR: UNIVERSITY OF WISCONSIN. CONTRACT NO: HHSN261201200033I, TASK ORDER: HHSN261000012. FROM 9/1
|
261201200033I
|
$1,485,915
|
UNKNOWN, UNKNOWN
|
UNIVERSITY OF WISCONSIN-MADISON
|
|
402 -- CHEMOPREVENTION OF COLORECTAL CANCER . CONTRACTOR: UNIVERSITY OF OKLAHOMA, HEALTH SCIENCES CENTER, DUNS: 878648294. CONTRACT NO: HHSN261500038I, TASK ORDER HHSN26100011. FROM 9/15/17 TO 9/14/
|
261201500038I
|
$1,236,052
|
UNKNOWN, UNKNOWN
|
UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR
|
Relevant funding data is only available when one cancer type or one research topic is selected.
|